Matches in SemOpenAlex for { <https://semopenalex.org/work/W336889637> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W336889637 endingPage "9" @default.
- W336889637 startingPage "597" @default.
- W336889637 abstract "The treatment of patients with recurrent ovarian carcinoma after failure of first and second-line chemotherapy is still debated. Chemical agents used for third and fourth-line therapy usually yield poor results with severe toxic side effects.To summarize our experience with goserelin in the treatment of patients with recurrent ovarian cancer.From September 1996 to June 1999 we administered goserelin, 3.6 mg subcutaneously every 4 weeks, to 15 patients with advanced and recurrent epithelial ovarian cancer (median age 59.0, median performance status 3.0).Seven of 15 eligible patients relapsed after platinum-based chemotherapy (3 of them also received paclitaxel and another 2 received tamoxifen). Four patients relapsed after carboplatin and paclitaxel, one of whom was treated with topotecan thereafter. Two patients relapsed after single-agent paclitaxel. Two patients with advanced disease and poor performance status without previous treatment received only goserelin. There was one complete response (6.7%) and 1 partial response (6.7%) lasting 8 and 14 months respectively (overall response rate 13.4%). In addition, the disease stabilized in three patients (20%) for a median of 7.5 months. In 10 patients the disease progressed. There was no significant toxicity. Median survival of all patients was 5.8 months.Goserelin was helpful in one-third of our patients with advanced and refractory ovarian cancer. It is an easy and non-toxic option for treating very ill or previously heavily treated patients." @default.
- W336889637 created "2016-06-24" @default.
- W336889637 creator A5017904857 @default.
- W336889637 creator A5024620871 @default.
- W336889637 creator A5057831157 @default.
- W336889637 creator A5065583844 @default.
- W336889637 creator A5077374548 @default.
- W336889637 date "2002-08-01" @default.
- W336889637 modified "2023-09-23" @default.
- W336889637 title "Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy." @default.
- W336889637 cites W1512107609 @default.
- W336889637 cites W1943690049 @default.
- W336889637 cites W1968937216 @default.
- W336889637 cites W2052821428 @default.
- W336889637 cites W2066490841 @default.
- W336889637 cites W2117729836 @default.
- W336889637 cites W2167805334 @default.
- W336889637 cites W2410697063 @default.
- W336889637 cites W2411032314 @default.
- W336889637 cites W24553618 @default.
- W336889637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12183859" @default.
- W336889637 hasPublicationYear "2002" @default.
- W336889637 type Work @default.
- W336889637 sameAs 336889637 @default.
- W336889637 citedByCount "3" @default.
- W336889637 countsByYear W3368896372016 @default.
- W336889637 crossrefType "journal-article" @default.
- W336889637 hasAuthorship W336889637A5017904857 @default.
- W336889637 hasAuthorship W336889637A5024620871 @default.
- W336889637 hasAuthorship W336889637A5057831157 @default.
- W336889637 hasAuthorship W336889637A5065583844 @default.
- W336889637 hasAuthorship W336889637A5077374548 @default.
- W336889637 hasConcept C121608353 @default.
- W336889637 hasConcept C126322002 @default.
- W336889637 hasConcept C141071460 @default.
- W336889637 hasConcept C143998085 @default.
- W336889637 hasConcept C2776694085 @default.
- W336889637 hasConcept C2777176818 @default.
- W336889637 hasConcept C2777292972 @default.
- W336889637 hasConcept C2778043895 @default.
- W336889637 hasConcept C2778239845 @default.
- W336889637 hasConcept C2780427987 @default.
- W336889637 hasConcept C2781209748 @default.
- W336889637 hasConcept C2781451048 @default.
- W336889637 hasConcept C530470458 @default.
- W336889637 hasConcept C71924100 @default.
- W336889637 hasConceptScore W336889637C121608353 @default.
- W336889637 hasConceptScore W336889637C126322002 @default.
- W336889637 hasConceptScore W336889637C141071460 @default.
- W336889637 hasConceptScore W336889637C143998085 @default.
- W336889637 hasConceptScore W336889637C2776694085 @default.
- W336889637 hasConceptScore W336889637C2777176818 @default.
- W336889637 hasConceptScore W336889637C2777292972 @default.
- W336889637 hasConceptScore W336889637C2778043895 @default.
- W336889637 hasConceptScore W336889637C2778239845 @default.
- W336889637 hasConceptScore W336889637C2780427987 @default.
- W336889637 hasConceptScore W336889637C2781209748 @default.
- W336889637 hasConceptScore W336889637C2781451048 @default.
- W336889637 hasConceptScore W336889637C530470458 @default.
- W336889637 hasConceptScore W336889637C71924100 @default.
- W336889637 hasIssue "8" @default.
- W336889637 hasLocation W3368896371 @default.
- W336889637 hasOpenAccess W336889637 @default.
- W336889637 hasPrimaryLocation W3368896371 @default.
- W336889637 hasRelatedWork W1990427150 @default.
- W336889637 hasRelatedWork W1994926318 @default.
- W336889637 hasRelatedWork W2024576940 @default.
- W336889637 hasRelatedWork W2054291341 @default.
- W336889637 hasRelatedWork W2061440113 @default.
- W336889637 hasRelatedWork W2092909014 @default.
- W336889637 hasRelatedWork W2253817994 @default.
- W336889637 hasRelatedWork W2443311901 @default.
- W336889637 hasRelatedWork W2461409983 @default.
- W336889637 hasRelatedWork W2466209479 @default.
- W336889637 hasVolume "4" @default.
- W336889637 isParatext "false" @default.
- W336889637 isRetracted "false" @default.
- W336889637 magId "336889637" @default.
- W336889637 workType "article" @default.